Eli Lilly and Company announced on Monday that its investigational obesity pill, Foundayo, has achieved significant reductions in the severity of obstructive sleep apnea (OSA), the most prevalent sleep-related breathing disorder, in patients with obesity during a pivotal late-stage clinical trial. This development marks a substantial step forward in the treatment landscape for OSA, a condition with profound health implications and limited pharmacological options. The pharmaceutical giant intends to submit its findings to the U.S. Food and Drug Administration (FDA) by the end of the year, seeking approval for the daily oral medication for adults suffering from moderate-to-severe OSA who are also classified as obese or overweight.
This latest success positions Foundayo, which saw its U.S. launch in April for obesity management, as another promising GLP-1 receptor agonist from Lilly’s pipeline to address OSA. Its predecessor, Eli Lilly’s blockbuster weight loss injectable, Zepbound (tirzepatide), made history in December 2024 by becoming the first medication to receive U.S. FDA approval for the treatment of OSA. The advent of these pharmacological solutions signals a transformative shift from primarily device-based therapies to a more accessible and potentially more adherent treatment paradigm.
Understanding Obstructive Sleep Apnea: A Global Health Burden
Obstructive sleep apnea is characterized by repeated episodes of interrupted breathing during sleep, caused by the narrowing or complete collapse of the upper airway. These nocturnal breathing cessations can lead to precipitous drops in blood oxygen levels and surges in blood pressure, triggering a cascade of serious health complications. The long-term consequences of untreated OSA include an elevated risk of hypertension, coronary artery disease, heart failure, stroke, type 2 diabetes, and even sudden cardiac death. Beyond these severe medical outcomes, OSA significantly impairs quality of life, leading to chronic fatigue, impaired cognitive function, reduced productivity, and an increased risk of accidents.
The global prevalence of OSA is staggering, affecting an estimated 936 million adults aged 30 to 69 worldwide, according to a landmark study published in The Lancet Respiratory Medicine. In the United States alone, the National Council on Aging estimates that approximately 80 million individuals aged 20 and over live with the condition. Despite its widespread impact, OSA remains largely underdiagnosed. Lilly highlighted in its release that a significant majority of affected individuals have never received a formal diagnosis, largely due to a lack of awareness, barriers to diagnostic testing, and the insidious nature of its symptoms, which are often dismissed as mere snoring or fatigue. This substantial diagnostic gap underscores the critical need for effective and accessible treatment options.
The Role of GLP-1 Agonists: A Paradigm Shift
The success of Foundayo and Zepbound in treating OSA is intrinsically linked to their mechanism of action as GLP-1 receptor agonists. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that plays a crucial role in glucose metabolism and appetite regulation. GLP-1 receptor agonists mimic the action of natural GLP-1, leading to several beneficial effects:
- Weight Loss: They slow gastric emptying, increase satiety, and reduce food intake, leading to significant and sustained weight reduction. Obesity is a primary risk factor for OSA, as excess fat deposits around the neck can narrow the airway.
- Anti-inflammatory Effects: GLP-1s have demonstrated anti-inflammatory properties, which may mitigate the systemic inflammation associated with both obesity and OSA.
- Potential Direct Airway Effects: While weight loss is a primary driver, ongoing research explores whether GLP-1s might also have direct effects on airway muscle tone or respiratory drive, though this is less established.
The introduction of these medications represents a significant advancement over existing OSA treatments. For decades, the primary non-surgical intervention has been Continuous Positive Airway Pressure (CPAP) therapy. While highly effective when used consistently, CPAP machines involve wearing a mask connected to an air pump during sleep, which many patients find cumbersome, uncomfortable, or claustrophobic. Adherence to CPAP therapy remains a significant challenge, with studies showing that a substantial percentage of patients fail to use the device as prescribed, thus limiting its real-world effectiveness. Other options include oral appliances, which reposition the jaw, and various surgical interventions, which are invasive and not suitable for all patients.
Dr. Thomas Seck, senior vice president of product development for Lilly Cardiometabolic Health, articulated the significance of these findings: "Foundayo is already making a difference for people living with obesity, and with plans to submit these results to the FDA by the end of the year, we could have the opportunity to help people living with OSA." This statement underscores Lilly’s strategic focus on addressing co-morbidities associated with obesity, leveraging the broad therapeutic potential of its GLP-1 portfolio.
Detailed Trial Results: Foundayo’s Efficacy Profile
The late-stage clinical program for Foundayo in OSA involved two independent, randomized, placebo-controlled studies, designed to assess the drug’s efficacy and safety across different patient populations.
The first study enrolled 363 patients who were either unable to tolerate or unwilling to use PAP therapy, representing a significant unmet medical need. This group often struggles with limited treatment alternatives. The second study included 349 individuals who had been consistently using PAP therapy for at least three months prior to screening and continued their PAP treatment throughout the trial, allowing for an assessment of Foundayo as an adjunctive therapy.
In both studies, patients initiated Foundayo at a low dose, which was then gradually titrated upwards at four-week intervals to achieve optimal therapeutic levels, a common practice for GLP-1 medications to manage potential gastrointestinal side effects.
The primary endpoint for both trials was the change in the Apnea-Hypopnea Index (AHI) from baseline to 52 weeks. The AHI is a widely recognized diagnostic and severity measure for OSA, quantifying the average number of apnea (complete cessation of breathing) and hypopnea (partial reduction in breathing) events per hour of sleep. An AHI of 5 to 15 events/hour indicates mild OSA, 15 to 30 indicates moderate, and greater than 30 indicates severe OSA.
Key Findings from the Foundayo Trials:
-
PAP-Naïve Group (Study 1): Patients in this cohort who received Foundayo experienced an average reduction of 21.1 AHI events per hour at 52 weeks. This was a stark contrast to the placebo group, which saw a modest average reduction of 4.8 AHI events per hour. Foundayo also successfully met the trial’s secondary goal in this group, demonstrating an overall AHI reduction of 43.8% from baseline, compared to a mere 6.3% decrease for placebo. Crucially, 31.5% of participants in the Foundayo arm achieved the criteria for remission or improvement to mild OSA (defined as an AHI below 5 or between 5-15, respectively, alongside a significant percentage reduction). This indicates a substantial improvement in the severity of their condition, potentially alleviating the need for other interventions.
-
PAP-Adherent Group (Study 2): For patients who continued their PAP therapy alongside Foundayo, the results were similarly impressive. The Foundayo group showed an average reduction of 18.3 AHI events per hour at 52 weeks, significantly outperforming the placebo group, which had an average reduction of 5.5 AHI events per hour. In terms of overall percentage reduction, Foundayo led to a 27.5% decrease in AHI, compared to a 3% decrease for placebo. Within this group, 19.6% of participants on Foundayo plus PAP therapy met the criteria for remission or improvement to mild OSA. These findings suggest that Foundayo can provide additional benefits even for patients who are already compliant with PAP, potentially improving their overall sleep quality and reducing residual events.
Beyond AHI, Foundayo also demonstrated positive effects on the sleep apnea-specific hypoxic burden, a critical measure indicating the depth and duration of oxygen desaturation events during sleep. This metric, which is directly linked to cardiovascular risk, fell by 55.9% in the PAP-naïve group and 45.8% in the PAP-adherent group. This reduction in hypoxic burden suggests a significant improvement in the physiological stress placed on the cardiovascular system by OSA.
Consistent with its known effects, Foundayo also facilitated an average weight loss of approximately 11% across both study groups at 52 weeks. Furthermore, the pill was shown to lower a marker of inflammation, indicating broader metabolic benefits that may contribute to the overall improvement in OSA severity.
Safety and Tolerability Profile
Eli Lilly stated that the safety data and tolerability profile of Foundayo in these OSA trials were generally consistent with previous clinical studies conducted for obesity. The most common side effects reported were gastrointestinal in nature, including nausea, diarrhea, constipation, and vomiting. These adverse events were predominantly mild to moderate in severity, aligning with the established profile of GLP-1 receptor agonists.
Regarding discontinuation rates due to side effects:
- In the PAP-naïve group, 12% of Foundayo participants discontinued the trial due to side effects, compared to 3.8% in the placebo group.
- In the PAP-adherent group, 6.8% of Foundayo participants discontinued due to side effects, compared to 0.6% in the placebo group.
While the discontinuation rates were higher in the Foundayo arms, they are generally considered manageable within the context of chronic disease treatment, especially given the significant clinical benefits observed. Patient education and careful dose titration strategies are typically employed to mitigate these effects.
Broader Implications and Future Outlook
The potential approval of Foundayo for OSA would have far-reaching implications across the healthcare spectrum.
- For Patients: It offers a much-needed, non-invasive, and potentially more convenient treatment alternative to cumbersome CPAP machines. Improved adherence to treatment could lead to better long-term health outcomes, enhanced quality of life, and reduced risk of associated cardiovascular and metabolic complications. For the millions of undiagnosed individuals, the availability of an oral medication might encourage more people to seek diagnosis and treatment.
- For Healthcare Providers: Physicians will gain another powerful tool in their arsenal to combat OSA, particularly for patients with co-morbid obesity who struggle with existing therapies. It could simplify treatment pathways and improve patient engagement.
- For Public Health: Addressing the vast burden of undiagnosed and undertreated OSA could have a significant positive impact on public health. Reducing the incidence of hypertension, heart failure, and stroke linked to OSA could alleviate strain on healthcare systems and improve overall population health metrics. The economic burden of OSA, estimated to be billions of dollars annually in the U.S. alone due to healthcare costs, lost productivity, and accidents, could also see a reduction.
- For Eli Lilly and the Pharmaceutical Market: Lilly is cementing its leadership in the burgeoning GLP-1 market. With Zepbound already approved for OSA and Foundayo on the horizon, the company is strategically expanding the therapeutic applications of its weight-loss medications. This diversification into new indications like OSA represents a significant market opportunity, potentially generating billions in additional revenue as these conditions affect a massive global population. The success also intensifies competition in the GLP-1 space, prompting other pharmaceutical companies to explore similar expanded indications for their own weight-loss therapies.
The anticipated FDA filing by year-end sets the stage for a potential regulatory decision in late 2025 or early 2026. If approved, Foundayo would join Zepbound in offering a revolutionary pharmacological approach to OSA, heralding a new era in the management of this widespread and often debilitating condition. The ongoing scientific exploration of GLP-1 agonists continues to unveil their multifaceted therapeutic potential, promising a future where conditions like obesity and its complex array of co-morbidities can be managed with unprecedented effectiveness.
